News for Cybin Inc. (CYBN.NE)

The consensus price target hints at a 988.7% upside potential for Cybin Inc. (CYBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Significant Transaction in Cybin Inc On December 31, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) executed a notable transaction involving Cybin Inc, a

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

– Launched strategic clinical site partnerships to accelerate PARADIGM, a multinational pivotal Phase 3 program evaluating CYB003 for the adjunctive treatment of ma…

The average of price targets set by Wall Street analysts indicates a potential upside of 952.2% in Cybin Inc. (CYBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Cybin updated the market with impressive 12-month efficacy data for its CYB003 Phase 2 trial. Explore more details here.

– Strategic Partnership Agreements will facilitate collaboration among sites, cultivate long term partnerships, enhance efficiency in trial operations, and improve …

TORONTO —

– Poster presentations highlight clinical data across Cybin’s CYB003 deuterated psilocin and DMT programs – – Poster presentations highlight clinical data across C…

On November 25, 2024, TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio) made a significant move by acquiring an additional 705,433 shares of Cybin Inc (CYBN) at a

Health stocks tumbled as vaccine sceptic RFK Jr. was named by President-elect Trump to head the Department of Health and Human Services.

It’s been one wild ride for Bright Minds Biosciences (NASDAQ: DRUG), which skyrocketed an eye-popping 5,900% this week! Yes, you read that right—nearly six

Numinus Wellness Inc. , a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, wishes to...

A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub

Clinical-stage psychedelics biotech Cybin Inc. (NYSE: CYBN) released its financial results for second quarter ended September 30, 2023.

First Person Inc is setting up a psychedelic mushroom company in Jamaica for research and development, with an initial outlay of US$500,000. The funds would come from the Canadian company’s pending initial public offering of shares that’s aimed at...

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Cybin Officially Owns Small Pharma, Gets Three New International Patents Granted

Psychedelics companies Cybin Inc. (NYSE: CYBN) and Small Pharma Inc. (OTCQB: DMTTF) have completed their August acquisition agreement.